First Tracks Biotherapeutics completed its spin-off from AnaptysBio on April 20, 2026, and began trading under the symbol TRAX. For the nine months ended September 30, 2026, the company reported a net loss of $115.2 million, driven by $83.4 million in research and development expenses for its clinical-stage antibody therapies.
First Tracks Biotherapeutics reported Q3 2026 financial results, highlighting a pro forma cash position of $343 million following a $200 million private placement. The company reported positive Phase 1b data for its lead candidate ANB033 in celiac disease and plans to initiate late-stage clinical development in 2027.
“ANB033, a subcutaneously administered CD122 antagonist designed to inhibit signaling of both IL-15 and IL-2 on immune cells, demonstrated statistically significant protection against gluten-induced intestinal damage and symptoms and was well tolerated in the Phase 1b gluten-challenge cohort. These data support our plans to progress ANB033 into late-stage development in 2027 in celiac disease as a potential treatment to prevent both acute symptoms and intestinal damage from gluten exposure despite general adherence to a gluten-free diet.”
Daniel Faga, president and chief executive officer